DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer

被引:73
作者
Nair, Varun Sasidharan [1 ]
Toor, Salman M. [1 ]
Taha, Rowaida Z. [1 ]
Shaath, Hibah [1 ]
Elkord, Eyad [1 ]
机构
[1] Hamad Bin Khalifa Univ, Qatar Fdn, Coll Sci & Engn, Canc Res Ctr,Qatar Biomed Res Inst, POB 5825, Doha, Qatar
关键词
Colorectal cancer; Immune checkpoints; PD-L1; Galectin-9; DNA methylation; Histone trimethylation; CPG ISLAND HYPERMETHYLATION; TUMOR-SUPPRESSOR GENES; TET PROTEINS; 5-HYDROXYMETHYLCYTOSINE; DEMETHYLATION; IMMUNOTHERAPY; TARGETS;
D O I
10.1186/s13148-018-0539-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Colorectal cancer (CRC) is the third most commonly diagnosed human malignancy worldwide. Upregulation of inhibitory immune checkpoints by tumor-infiltrating immune cells (TIICs) or their ligands by tumor cells leads to tumor evasion from host immunosurveillance. Changes in DNA methylation pattern and enrichment of methylated histone marks in the promoter regions could be major contributors to the upregulation of immune checkpoints (ICs) in the tumor microenvironment (TME). Methods: Relative expressions of various immune checkpoints and ligands in colon normal tissues (NT) and colorectal tumor tissues (TT) were assessed by qRT-PCR. The epigenetic modifications behind this upregulation were determined by investigating the CpG methylation status of their promoter regions using bisulfate sequencing. Distributions of histone 3 lysine 9 trimethylation (H3K9me3) and histone 3 lysine 27 trimethylation (H3K27me3) in promoter regions of these genes were assessed by chromatin immunoprecipitation (ChIP) assay. Results: We found that the expression levels of PD-1, CTLA-4, TIM-3, TIGIT, PD-L1, and galectin-9 were significantly higher in colorectal tumor tissues, compared with colon normal tissues. To study the role of DNA methylation, we checked the promoter CpG methylation of ICs and ligands and found that only CTLA-4 and TIGIT, among other genes, were significantly hypomethylated in TT compared with NT. Next, we checked the abundance of repressive histones (H3K9me3 and H3K27me3) in the promoter regions of ICs/ligands. We found that bindings of H3K9me3 in PD-1 and TIGIT promoters and H3K27me3 in CTLA-4 promotor were significantly lower in TT compared with NT. Additionally, bindings of both H3K9me3 and H3K27me3 in the TIM-3 promoter were significantly lower in TT compared with NT. Conclusion: This study shows that both DNA hypomethylation and H3K9me3 and H3K27me3 repressive histones are involved in upregulation of CTLA-4 and TIGIT genes. However, repressive histones, but not DNA hypomethylation, are involved in upregulation of PD-1 and TIM-3 genes in CRC tumor tissue. These epigenetic modifications could be utilized as diagnostic biomarkers for CRC.
引用
收藏
页数:9
相关论文
共 30 条
[1]   TET family dioxygenases and DNA demethylation in stem cells and cancers [J].
An, Jungeun ;
Rao, Anjana ;
Ko, Myunggon .
EXPERIMENTAL AND MOLECULAR MEDICINE, 2017, 49 :e323-e323
[2]   Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting [J].
Chaudhary, Belal ;
Elkord, Eyad .
VACCINES, 2016, 4 (03)
[3]   Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21 [J].
Derks, Sarah ;
Bosch, Linda J. W. ;
Niessen, Hanneke E. C. ;
Moerkerk, Peter T. M. ;
van den Bosch, Sandra M. ;
Carvalho, Beatriz ;
Mongera, Sandra ;
Voncken, J. Willem ;
Meijer, Gerrit A. ;
de Bruine, Adriaan P. ;
Herman, James G. ;
van Engeland, Manon .
CARCINOGENESIS, 2009, 30 (06) :1041-1048
[4]   Results and challenges of immune checkpoint inhibitors in colorectal cancer [J].
Emambux, Sheik ;
Tachon, Gaelle ;
Junca, Audelaure ;
Tougeron, David .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (05) :561-573
[5]   CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future [J].
Esteller, M .
ONCOGENE, 2002, 21 (35) :5427-5440
[6]   Loss of 5-hydroxymethylcytosine in cancer: Cause or consequence? [J].
Ficz, Gabriella ;
Gribben, John G. .
GENOMICS, 2014, 104 (05) :352-357
[7]   Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens [J].
Gubin, Matthew M. ;
Zhang, Xiuli ;
Schuster, Heiko ;
Caron, Etienne ;
Ward, Jeffrey P. ;
Noguchi, Takuro ;
Ivanova, Yulia ;
Hundal, Jasreet ;
Arthur, Cora D. ;
Krebber, Willem-Jan ;
Mulder, Gwenn E. ;
Toebes, Mireille ;
Vesely, Matthew D. ;
Lam, Samuel S. K. ;
Korman, Alan J. ;
Allison, James P. ;
Freeman, Gordon J. ;
Sharpe, Arlene H. ;
Pearce, Erika L. ;
Schumacher, Ton N. ;
Aebersold, Ruedi ;
Rammensee, Hans-Georg ;
Melief, Cornelis J. M. ;
Mardis, Elaine R. ;
Gillanders, William E. ;
Artyomov, Maxim N. ;
Schreiber, Robert D. .
NATURE, 2014, 515 (7528) :577-+
[8]   The hallmarks of cancer [J].
Hanahan, D ;
Weinberg, RA .
CELL, 2000, 100 (01) :57-70
[9]   Augmenting antitumor immune responses with epigenetic modifying agents [J].
Heninger, Erika ;
Krueger, Timothy E. G. ;
Lang, Joshua M. .
FRONTIERS IN IMMUNOLOGY, 2015, 6
[10]   Connections between TET proteins and aberrant DNA modification in cancer [J].
Huang, Yun ;
Rao, Anjana .
TRENDS IN GENETICS, 2014, 30 (10) :464-474